To compare the efficacy of bevacizumab and rose
bengal photodynamic therapy (RB-PDT) in the treatment of corneal
Material and methods
study design included the induction of CNV by suture placement in three
groups of New Zealand rabbits: (1) a group with CNV without any
treatment; (2) a group treated with subconjunctival injection of
bevacizumab (25 mg/eye); (3) a group treated with intravenous injection
of rose bengal and exposed to 532 nm photodynamic therapy. For 4 weeks,
the animals were followed up by slit-lamp to analyze the extent of CNV,
evaluate the corneal protein secondary structure, and determine the
oxidative stress index (OSI).
After 4 weeks,
traces of neovascularization were observed only in the bevacizumab
treated group with grade 0.5. The contents of -helix and -sheet were
17% and 61% in CNV, 32%, and 46% in bevacizumab and 40% and 36% in
RB-PDT groups vs. 43% and 35% for the control group. Moreover, the
percentage changes in the total oxidative status (TOS) for CNV,
bevacizumab and RB-PDT groups were 97.1%, 14.6%, and 1.0%, respectively,
with respect to the control. The total antioxidant status (TAC) showed
no significant changes (p > 0.05) for both treated groups. The
percentage of changes in OSI was 15.9% and 1.3% in bevacizumab, and
RB-PDT treated groups compared with the control group.
modes of treatment were effective in the regression of CNV, but RB-PDT
was more efficient than bevacizumab by improving the corneal protein
secondary structure and the oxidative stress.
Bevacizumab, sold under the commercial name Avastin, is on the World Health Organization's List of Essential Medicine. Depending on which indication it's being used to treat, it can cost upwards of $100,000 per year per patient treated. Counties like Canada and the UK have placed restrictions on it's use because it's too expensive.
Avastin generates over $7 BILLION dollars in sales for Roche annually. Yet, here we are with a better product that could cost patients significantly less.
It's just a matter of time, folks.